| Name | Title | Contact Details |
|---|
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
Chicago Hospital Risk Pooling Program is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Visiting Nurse and Hospice for Vermont and New Hampshire (VNH) is a non‐profit organization that has provided home health and hospice care services in Vermont and New Hampshire since 1907. The agency is dedicated to delivering outstanding home- and community-based health and hospice services that enrich the lives of the people they serve. VNH makes home visits to people of all ages and all stages of life – regardless of ability to pay – and also provides communities with education and wellness programs. Currently, VNH serves more than 150 towns in Vermont and New Hampshire and covers 4,000 square miles. VNH caregivers provide services for more than 5,000 people each year and makes more than 150,000 home visits to people of all ages and at all stages of life.
Wichita Psychiatric Consultants is a Wichita, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.